LDS/Medical Tests/Troponin-I/T, Cardiac

Troponin-I/T, Cardiac

Troponin is a protein complex that regulates the contraction of striated muscle. It consists of three subunits that are located periodically along the thin filament of the myofibrils. Troponin C binds calcium, troponin T attaches to tropomyosin on the thin filament, and troponin I inhibits actomyosin ATPase.  All three types of troponin are present in both cardiac and skeletal muscle, but troponins I and T possess unique amino acid sequences in cardiac muscle, whereas troponin C is identical in both cardiac and skeletal muscle.  Hence, troponin C cannot be used in discriminating cardiac muscle damage.   The development of antibody tests for the cardiac-specific portions of troponins I and T have allowed for the detection of the cardiac forms (cTnI and cTnT), and assays for each have been developed and are in routine commercial use.  At the time of cardiac muscle damage, both troponins I and T are released from cardiac myocytes into the systemic circulation. Some institutions utilize troponoin T instead of troponin I.  There is no conslusive evidence that either is superior in diagnosing or assessing myocardial injury, and in fact numerous studies have pointed to the fact that the two tests are functionally equivalent.  The most important factor in selecting which to use therefore is analytic and clinical performance of the assay, whichever is used.  There is no method of correlating troponin I and troponin T results.  There is currently a lack of standardization of assays for Troponin I, but efforts are being made to improve this.  Troponin T is more often elevated in the setting of renal failure, but this may be related to the overall cardio-renal status rather than a false positive.

Troponin I (TnI) and troponin T (TnT) Troponins can be detected at 6 to 8 hours following onset of chest pain with peak concentrations at 12 to 24 hours, and remain elevated for up to 14 days, providing more opportunity for detecting myocardial infarction, or excluding the diagnosis.  Troponin measurement is especially helpful in patients with non-ST-segment elevation MI (NSTEMI) since EKG findings may be equivocal in these patients presenting with chest pain. Current guidelines suggest serial cTn levels, with a second drawn at 6 - 12 hours after presentation in those with equivocal EKG findings and a low or negative initial cTn.  Because of their cardiac specificity and sensitivity, both troponin I and T have been used as a reliable marker in the diagnosis of perioperative myocardial infarction in patients undergoing cardiac surgery. It also provides useful information for evaluating patients with unstable angina, a condition implying increased risk of myocardial infarction and sudden death. Other conditions resulting in myocardial cell damage can result in elevated cardiac troponin levels, including myocarditis, cardiac surgery, angina, unstable angina, congestive heart failure, and non-cardiac related causes such as renal failure and pulmonary embolism.  Interpretation therefore should always be made with knowledge of the clinical context.  Cardiac troponin measurements can be used as an aid in the diagnosis and treatment of myocardial infarction and in the risk stratification of patients with acute coronary syndromes with respect to their relative risk of mortality.

  • Diagnosis of or exclusion of acute myocardial infarction after onset of symptoms
  • As an aid in differentiation of unstable angina and acute myocardial infarction
  • As an aid in differentiation of acute myocardial infarction from other illness-related myocardial damage such as chronic heart disease, heart surgery, nonischemic dilated cardiomyopathies, and trauma
  • Differential diagnosis of heart muscle damage from skeletal muscle damage
  • Evaluating and following acute coronary syndromes with prognostic implication

Increased in:

  • Acute myocardial infarction (usually detected after 4 to 8 hours following onset of chest pain with peak concentrations at 12 to 16 hours and remains elevated for 5 to 9 days)
  • Acute coronary syndromes
  • Cardiac trauma
  • Myocardial damage following surgery and other cardiac interventions
  • Nonischemic dilated cardiomyopathy
  • Prolonged supraventricular tachycardia
  • Acute dissection of the ascending aorta
  • Slight elevations noted in patients with recent aggravated unstable angina, muscular disorders, central nervous system disorders, HIV infection, chronic renal failure, sepsis, lung diseases, and endocrine disorders

Not increased in:

  • Skeletal muscle disease such as muscle trauma, myopathy, myositis, dystrophy, noncardiac trauma, surgery, and rhabdomyolysis

<0.1 ng/mL)
>1.5 ng/mL (Diagnostic of acute myocardial infarction)
 

Enzyme Immunoassay (EIA), two-site sandwich chemiluminometric immunoassay assay (CLIA) two-site enzyme-linked immunosorbant assay (ELISA).

Serum (SST) or Plasma EDTA (Lavender).

If analysis is not to be performed within 4-6hr, specimens should be stored refrigerated for up to 24 hr.

Stability

  • Ambient: 4 hours
  • Refrigerated: 24 hours
  • Frozen: 30 days
CK, CK-MB, ALT, AST, Myoglobin, LDH, Comprehensive Metabolic Panel (CMP), Complete Blood Cell Count, Lipid Profile, Liver Profile.
1-3 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login